Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice

Identifieur interne : 003504 ( Main/Exploration ); précédent : 003503; suivant : 003505

The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice

Auteurs : M. D. Coleman [Royaume-Uni] ; G. W. Mihaly [Royaume-Uni] ; S. A. Ward [Royaume-Uni] ; G. Edwards [Royaume-Uni] ; R. E. Howells [Royaume-Uni] ; A. M. Breckenridge [Royaume-Uni]

Source :

RBID : ISTEX:4DA1943F1F62BD9CE4F4C01018383A9D5C4E48F7

English descriptors

Abstract

The pharmacokinetics and mass fate in mice, of pyrimethamine (425 mg kg−1 s.o.) administered subcutaneously either as the base (BASE) or the pamoate salt (PAM) in an injectable oil mixture (benzyl benzoate‐peanut oil 50:50 v/v) have been evaluated. Maximum measured plasma pyrimethamine levels after BASE were attained within 24 h, and were twice as high as after PAM. 25% of animals dosed with BASE died; among the survivors plasma drug levels fell rapidly below the minimum inhibitory concentration (MIC) for Plasmodium berghei (100–200 ng ml−1) by 5 weeks. In contrast, no mice dosed with PAM died and plasma levels were sustained above the MIC for 13 weeks, drug still being detectable in plasma after four months. Overall, there was no significant difference between areas under the curve from zero time to the time of the final sampling of pyrimethamine following PAM or BASE. The rapid initial elimination of 14C‐radioactivity (2ṁ64 ± 0ṁ47% dose day−1 over 4 weeks) seen after dosage with [14C]BASE reflected the plasma disposition of pyrimethamine in the mice dosed with BASE. 90% of the excreted 14C was eliminated by one month by which time less than 1% (0ṁ03 ± 0ṁ02%) of the [14C]BASE was recovered from the injection site. Both BASE and [14C]BASE studies suggest that exhaustion of this preparation occurred by 7 weeks. Excretion of 14C‐radioactivity after [14C]PAM was gradual and sustained with a low mean daily rate, that was maintained throughout the study i.e. 1ṁ21 ± 0ṁ17% day−1 (4 weeks), 0ṁ88 ± 0ṁ28% day−1 (8 weeks), 0ṁ5 ± 0ṁ31% day−1 (12 weeks), 0ṁ42 ± 0ṁ27% day−1 (16 weeks). At the end of the study, 7ṁ11 ± 1ṁ90% of the [14C]PAM remained in the dose site. No visible tissue reactions were observed to either preparation. Overall recovery of radioactivity was 85ṁ00 ± 11ṁ31% for both [14C]PAM and [14C]BASE. These studies indicate that the PAM preparation is worthy of further long term evaluation.

Url:
DOI: 10.1111/j.2042-7158.1985.tb04993.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice</title>
<author>
<name sortKey="Coleman, M D" sort="Coleman, M D" uniqKey="Coleman M" first="M. D." last="Coleman">M. D. Coleman</name>
</author>
<author>
<name sortKey="Mihaly, G W" sort="Mihaly, G W" uniqKey="Mihaly G" first="G. W." last="Mihaly">G. W. Mihaly</name>
</author>
<author>
<name sortKey="Ward, S A" sort="Ward, S A" uniqKey="Ward S" first="S. A." last="Ward">S. A. Ward</name>
</author>
<author>
<name sortKey="Edwards, G" sort="Edwards, G" uniqKey="Edwards G" first="G." last="Edwards">G. Edwards</name>
</author>
<author>
<name sortKey="Howells, R E" sort="Howells, R E" uniqKey="Howells R" first="R. E." last="Howells">R. E. Howells</name>
</author>
<author>
<name sortKey="Breckenridge, A M" sort="Breckenridge, A M" uniqKey="Breckenridge A" first="A. M." last="Breckenridge">A. M. Breckenridge</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4DA1943F1F62BD9CE4F4C01018383A9D5C4E48F7</idno>
<date when="1985" year="1985">1985</date>
<idno type="doi">10.1111/j.2042-7158.1985.tb04993.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-GX6V4RWH-M/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D35</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001D35</idno>
<idno type="wicri:Area/Istex/Curation">001D35</idno>
<idno type="wicri:Area/Istex/Checkpoint">002263</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002263</idno>
<idno type="wicri:doubleKey">0022-3573:1985:Coleman M:the:sustained:release</idno>
<idno type="wicri:Area/Main/Merge">003578</idno>
<idno type="wicri:Area/Main/Curation">003504</idno>
<idno type="wicri:Area/Main/Exploration">003504</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice</title>
<author>
<name sortKey="Coleman, M D" sort="Coleman, M D" uniqKey="Coleman M" first="M. D." last="Coleman">M. D. Coleman</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, P.O. Box 147, Liverpool L69 3BX</wicri:regionArea>
<wicri:noRegion>Liverpool L69 3BX</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Correspondence address: Department of Pharmacology and Therapeutics, University of Liverpool, P.O. Box 147, Liverpool L69 3BX</wicri:regionArea>
<wicri:noRegion>Liverpool L69 3BX</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mihaly, G W" sort="Mihaly, G W" uniqKey="Mihaly G" first="G. W." last="Mihaly">G. W. Mihaly</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, P.O. Box 147, Liverpool L69 3BX</wicri:regionArea>
<wicri:noRegion>Liverpool L69 3BX</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ward, S A" sort="Ward, S A" uniqKey="Ward S" first="S. A." last="Ward">S. A. Ward</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, P.O. Box 147, Liverpool L69 3BX</wicri:regionArea>
<wicri:noRegion>Liverpool L69 3BX</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Edwards, G" sort="Edwards, G" uniqKey="Edwards G" first="G." last="Edwards">G. Edwards</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Departments of Tropical Medicine, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA</wicri:regionArea>
<wicri:noRegion>Liverpool L3 5QA</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Howells, R E" sort="Howells, R E" uniqKey="Howells R" first="R. E." last="Howells">R. E. Howells</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Departments of Parasitology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA</wicri:regionArea>
<wicri:noRegion>Liverpool L3 5QA</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Breckenridge, A M" sort="Breckenridge, A M" uniqKey="Breckenridge A" first="A. M." last="Breckenridge">A. M. Breckenridge</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Pharmacology and Therapeutics, University of Liverpool, P.O. Box 147, Liverpool L69 3BX</wicri:regionArea>
<wicri:noRegion>Liverpool L69 3BX</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Journal of Pharmacy and Pharmacology</title>
<title level="j" type="alt">JOURNAL OF PHARMACY AND PHARMACOLOGY</title>
<idno type="ISSN">0022-3573</idno>
<idno type="eISSN">2042-7158</idno>
<imprint>
<biblScope unit="vol">37</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="878">878</biblScope>
<biblScope unit="page" to="883">883</biblScope>
<biblScope unit="page-count">6</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="1985-12">1985-12</date>
</imprint>
<idno type="ISSN">0022-3573</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0022-3573</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Base preparation</term>
<term>Coleman</term>
<term>Cycloguanil pamoate</term>
<term>Dose site</term>
<term>Excretion</term>
<term>Excretion rate</term>
<term>Howells</term>
<term>Hydrogen peroxide</term>
<term>Injection site</term>
<term>Injection sites</term>
<term>Mass fate</term>
<term>Medical research council</term>
<term>Overall recovery</term>
<term>Pamoate</term>
<term>Pamoate salt</term>
<term>Peanut benzoate</term>
<term>Plasma disposition</term>
<term>Plasma levels</term>
<term>Present report</term>
<term>Present study</term>
<term>Pyrimethamine</term>
<term>Pyrimethamine base</term>
<term>Pyrimethamine pamoate</term>
<term>Pyrimethamine plasma concentrations</term>
<term>Pyrimethamine preparations</term>
<term>Radioactivity</term>
<term>Specific activity</term>
<term>Statistical analysis</term>
<term>Tissue localization</term>
<term>Tissue solubilizer</term>
<term>Tropical medicine</term>
<term>Unchanged drug</term>
<term>Urine</term>
<term>Visible tissue reactions</term>
<term>Weekly intervals</term>
<term>Weeks post dose</term>
<term>World health organisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The pharmacokinetics and mass fate in mice, of pyrimethamine (425 mg kg−1 s.o.) administered subcutaneously either as the base (BASE) or the pamoate salt (PAM) in an injectable oil mixture (benzyl benzoate‐peanut oil 50:50 v/v) have been evaluated. Maximum measured plasma pyrimethamine levels after BASE were attained within 24 h, and were twice as high as after PAM. 25% of animals dosed with BASE died; among the survivors plasma drug levels fell rapidly below the minimum inhibitory concentration (MIC) for Plasmodium berghei (100–200 ng ml−1) by 5 weeks. In contrast, no mice dosed with PAM died and plasma levels were sustained above the MIC for 13 weeks, drug still being detectable in plasma after four months. Overall, there was no significant difference between areas under the curve from zero time to the time of the final sampling of pyrimethamine following PAM or BASE. The rapid initial elimination of 14C‐radioactivity (2ṁ64 ± 0ṁ47% dose day−1 over 4 weeks) seen after dosage with [14C]BASE reflected the plasma disposition of pyrimethamine in the mice dosed with BASE. 90% of the excreted 14C was eliminated by one month by which time less than 1% (0ṁ03 ± 0ṁ02%) of the [14C]BASE was recovered from the injection site. Both BASE and [14C]BASE studies suggest that exhaustion of this preparation occurred by 7 weeks. Excretion of 14C‐radioactivity after [14C]PAM was gradual and sustained with a low mean daily rate, that was maintained throughout the study i.e. 1ṁ21 ± 0ṁ17% day−1 (4 weeks), 0ṁ88 ± 0ṁ28% day−1 (8 weeks), 0ṁ5 ± 0ṁ31% day−1 (12 weeks), 0ṁ42 ± 0ṁ27% day−1 (16 weeks). At the end of the study, 7ṁ11 ± 1ṁ90% of the [14C]PAM remained in the dose site. No visible tissue reactions were observed to either preparation. Overall recovery of radioactivity was 85ṁ00 ± 11ṁ31% for both [14C]PAM and [14C]BASE. These studies indicate that the PAM preparation is worthy of further long term evaluation.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
</country>
</list>
<tree>
<country name="Royaume-Uni">
<noRegion>
<name sortKey="Coleman, M D" sort="Coleman, M D" uniqKey="Coleman M" first="M. D." last="Coleman">M. D. Coleman</name>
</noRegion>
<name sortKey="Breckenridge, A M" sort="Breckenridge, A M" uniqKey="Breckenridge A" first="A. M." last="Breckenridge">A. M. Breckenridge</name>
<name sortKey="Coleman, M D" sort="Coleman, M D" uniqKey="Coleman M" first="M. D." last="Coleman">M. D. Coleman</name>
<name sortKey="Edwards, G" sort="Edwards, G" uniqKey="Edwards G" first="G." last="Edwards">G. Edwards</name>
<name sortKey="Howells, R E" sort="Howells, R E" uniqKey="Howells R" first="R. E." last="Howells">R. E. Howells</name>
<name sortKey="Mihaly, G W" sort="Mihaly, G W" uniqKey="Mihaly G" first="G. W." last="Mihaly">G. W. Mihaly</name>
<name sortKey="Ward, S A" sort="Ward, S A" uniqKey="Ward S" first="S. A." last="Ward">S. A. Ward</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003504 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003504 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4DA1943F1F62BD9CE4F4C01018383A9D5C4E48F7
   |texte=   The sustained release of pyrimethamine base or pyrimethamine pamoate from a biodegradable injectable depot preparation in mice
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021